Gilead Sciences, Inc.

Zhenhong R Cai

Hyung-Jung Pyun

Haolun Jin

Mingzhe Ji

Scott E Lazerwith

Jeromy J Cottell

Elizabeth M Bacon

Philip Anthony Morganelli

James G Taylor

Lianhong Xu

Ryan McFadden

Michael R Mish

Manoj C Desai

Hong Yang

Teresa Alejandra Trejo Martin

Xiaowu Chen

Salman Y Jabri

Aesop Cho

Michael L Mitchell

Jie Xu

Ana Zurisadai Gonzalez Buenrostro

Xiaochun Han

Johannes H Voigt

Yingmei Qi

Choung U Kim

Eda Y Canales

Rick Andrew Lee

Richard Y Huang

Michael O'Neil Hanrahan Clarke

Hongyan Guo

Petr Jansa

Richard Pastor

Adam James Schrier

Samuel E Metobo

Edward Doerffler

Michael Sangi

Qiaoyin Wu

Roland D Saito

Joshua J Van Veldhuizen

Daniel H Byun

Jennifer Alissa Loyer-Drew

Xiaoning C Sheng

Marina Shatskikh

Manuel Munoz

Laurent P Debien

Amy Lee

Rachael A Lansdown

Timothy R Hansen

Ryan Mcfadden

Johannes Voigt

Jin Haolun

Phillip Anthony Morganelli

The present disclosure relates to novel compounds for use in therapeutic treatment of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to processes and intermediates for the preparation of such compounds, methods of using such compounds and pharmaceutical compositions comprising the compounds described herein.

Inhibitors of peptidylarginine deiminases

Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R, X, W, Y, Y, Z, and Zare as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Substituted 1,4-methanopyrido[1',2&#x2032;:4,5]pyrazino[1,2-a]pyrimidines for treating viral infections

The invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of Formula I, processes for preparing compounds of Formula I, therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS symptoms in a mammal using compounds of Formula I.

HIV protease inhibitors

Compounds disclosed herein including compounds of Formula I: and salts thereof are provided. Pharmaceutical compositions comprising compounds disclosed herein, processes for preparing compounds disclosed herein, intermediates useful for preparing compounds disclosed herein and therapeutic methods for treating an HIV infection using compounds disclosed herein are also provided.

Therapeutic compounds

Substituted 3,4,5,6,8,10,14,14a-octahydro-2h-2,6-methanopyrido[1',2&#x2032;:4,5]pyrazino[2,1-b][1,3]oxazocines and methods for treating viral infections

Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (Ia): including stereoisomers and pharmaceutically acceptable salts thereof, wherein A', R, Rand Rare as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Polycyclic-carbamoylpyridone compounds and their pharmaceutical use

Substituted 2,3,4,5,7,9,13,13a-octahydro-1,5-methanopyrido[1',2&#x2032;:4,5]pyrazino[1,2-a][1,3]diazepines and methods for treating viral infections

Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (Ia): including stereoisomers and pharmaceutically acceptable salts thereof, wherein A, A', Rand Rare as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

The present application includes novel inhibitors of HCV, compositions containing such compounds, therapeutic methods that include the administration of such compounds.

Antiviral compounds

Tricyclic compounds, protected intermediates thereof, and methods for inhibition of HIV-integrase are disclosed.

Integrase inhibitors

Growing community of inventors

Palo Alto, CA, United States of America

Zhenhong R Cai